161 related articles for article (PubMed ID: 35989151)
21. Evaluation of naloxone furnishing community pharmacies in San Francisco.
Nguyen AM; Kearney TE; Apollonio DE
J Am Pharm Assoc (2003); 2020; 60(6):1050-1057.e1. PubMed ID: 32948461
[TBL] [Abstract][Full Text] [Related]
22. Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial.
Pollini RA; Ozga JE; Joyce R; Xuan Z; Walley AY
Drug Alcohol Depend; 2022 Feb; 231():109259. PubMed ID: 34998246
[TBL] [Abstract][Full Text] [Related]
23. Assessment of naloxone availability in Georgia community pharmacies.
Stone RH; Hur S; Young HN
J Am Pharm Assoc (2003); 2020; 60(2):357-361. PubMed ID: 31866387
[TBL] [Abstract][Full Text] [Related]
24. Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states.
Hill LG; Loera LJ; Torrez SB; Puzantian T; Evoy KE; Ventricelli DJ; Eukel HN; Peckham AM; Chen C; Ganetsky VS; Yeung MS; Zagorski CM; Reveles KR
Drug Alcohol Depend; 2022 Aug; 237():109518. PubMed ID: 35691255
[TBL] [Abstract][Full Text] [Related]
25. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
Bailey AM; Wermeling DP
Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with naloxone availability and dispensing through Michigan's pharmacy standing order.
Dahlem CH; Myers M; Goldstick J; Stevenson JG; Gray G; Rockhill S; Dora-Laskey A; Kellenberg J; Brummett CM; Kocher KE
Am J Drug Alcohol Abuse; 2022 Jul; 48(4):454-463. PubMed ID: 35405078
[No Abstract] [Full Text] [Related]
27. Public Health and Pharmacy Partnerships in Opioid Harm Reduction: Responding to Community Needs.
Medina S; Tomaszewski R; Chhen S; Hanson A; Mueller A; Palombi LC
Prog Community Health Partnersh; 2021; 15(1):37-46. PubMed ID: 33775959
[TBL] [Abstract][Full Text] [Related]
28. A standardized team-based approach for identifying naloxone-eligible patients in a grocery store pharmacy.
Sexton SM; Armstrong A; Gatton O; Rhodes LA; Marciniak MW
J Am Pharm Assoc (2003); 2019; 59(4S):S95-S100. PubMed ID: 31231001
[TBL] [Abstract][Full Text] [Related]
29. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
Binswanger IA; Rinehart D; Mueller SR; Narwaney KJ; Stowell M; Wagner N; Xu S; Hanratty R; Blum J; McVaney K; Glanz JM
J Gen Intern Med; 2022 Aug; 37(11):2624-2633. PubMed ID: 35132556
[TBL] [Abstract][Full Text] [Related]
30. Analysis of naloxone access and primary medication nonadherence in a community pharmacy setting.
Connolly E; McCall KL; Couture S; Felton M; Piper BJ; Bratberg JP; Tu C
J Am Pharm Assoc (2003); 2022; 62(1):49-54. PubMed ID: 34736865
[TBL] [Abstract][Full Text] [Related]
31. Pharmacist counseling when dispensing naloxone by standing order: A secret shopper study of 4 chain pharmacies.
Contreras J; Baus C; Brandt C; Witry M; Peters J; Evoy KE
J Am Pharm Assoc (2003); 2021; 61(2):e94-e99. PubMed ID: 33153912
[TBL] [Abstract][Full Text] [Related]
32. Stocking and supplying naloxone: Findings from a representative sample of community pharmacies in Victoria, Australia.
Karthikeyan N; Xia T; Nielsen S; Picco L
Drug Alcohol Rev; 2024 Jul; 43(5):1305-1312. PubMed ID: 38691509
[TBL] [Abstract][Full Text] [Related]
33. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.
Green TC; Dauria EF; Bratberg J; Davis CS; Walley AY
Harm Reduct J; 2015 Aug; 12():25. PubMed ID: 26245865
[TBL] [Abstract][Full Text] [Related]
34. Pharmacist roles, training, and perceived barriers in naloxone dispensing: A systematic review.
Thakur T; Frey M; Chewning B
J Am Pharm Assoc (2003); 2020; 60(1):178-194. PubMed ID: 31371179
[TBL] [Abstract][Full Text] [Related]
35. Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.
Olsen A; Lawton B; Dwyer R; Taing MW; Chun KLJ; Hollingworth S; Nielsen S
Int J Drug Policy; 2019 Jul; 69():46-52. PubMed ID: 31078908
[TBL] [Abstract][Full Text] [Related]
36. Naloxone Accessibility Under the State Standing Order Across Mississippi.
Gravlee E; Ramachandran S; Cafer A; Holmes E; McGregor J; Jordan T; Rosenthal M
JAMA Netw Open; 2023 Jul; 6(7):e2321939. PubMed ID: 37410464
[TBL] [Abstract][Full Text] [Related]
37. Assessing pharmacy-based naloxone access using an innovative purchase trial methodology.
Pollini RA; Joyce R; Ozga-Hess JE; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2020; 60(6):853-860. PubMed ID: 32651116
[TBL] [Abstract][Full Text] [Related]
38. Legal changes to increase access to naloxone for opioid overdose reversal in the United States.
Davis CS; Carr D
Drug Alcohol Depend; 2015 Dec; 157():112-20. PubMed ID: 26507172
[TBL] [Abstract][Full Text] [Related]
39. An observational study of the extent of naloxone furnishing in California Central Valley community pharmacies.
Banawis M; Mah G; Mohsin R; Pobre J; Tracy D; Song AV; Apollonio DE
J Am Pharm Assoc (2003); 2023; 63(2):566-573. PubMed ID: 36476261
[TBL] [Abstract][Full Text] [Related]
40. Pharmacy leaders' beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community.
Donovan E; Bratberg J; Baird J; Burstein D; Case P; Walley AY; Green TC
Res Social Adm Pharm; 2020 Oct; 16(10):1493-1497. PubMed ID: 31983625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
